8-K - Quince Therapeutics, Inc. - 5.02
站内整理正文
Form 8-K - Current report: SEC Accession No. 0001193125-26-170572
Filing Date: 2026-04-22
Accepted: 2026-04-22 16:30:28
Documents: 11
Period of Report: 2026-04-22
Items: Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Quince Therapeutics, Inc. (Filer) CIK : 0001662774 (see all company filings) EIN. : 901024039 | State of Incorp.: CA | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 26884223 SIC : 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)
1 | 8-K | d27180d8k.htm iXBRL | 8-K
2 | XBRL TAXONOMY EXTENSION SCHEMA | qncx-20260422.xsd | EX-101.SCH
3 | XBRL TAXONOMY EXTENSION LABEL LINKBASE | qncx-20260422_lab.xml | EX-101.LAB
4 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE | qncx-20260422_pre.xml | EX-101.PRE